# DESCRIPTION

## CROSS REFERENCE

- claim priority to provisional patent application

## FIELD OF THE INVENTION

- relate to GAB1 inhibitors and cancer treatment

## BACKGROUND OF THE INVENTION

- motivate GAB1 overexpression in cancer
- describe GAB1 structure and function
- summarize limitations of current cancer treatments
- introduce PH domain structure models
- describe challenges of structural prediction
- motivate targeting GAB1 PH domain for cancer treatment

## SUMMARY OF THE INVENTION

- summarize GAB1 PH domain as therapeutic target
- describe virtual screening and hit compounds
- summarize potential of GAB1 PH domain inhibitors

## DESCRIPTION OF PREFERRED EMBODIMENTS

- define alkyl
- define alkenyl
- define alkynyl
- specify limitations of alkenyl and alkynyl
- define alkoxy
- define aryl
- define aralkyl
- define heterocycle and heteroaryl
- define cycloalkyl and cycloalkylalkyl
- define halogen and related terms
- define various amine and hydroxy terms
- define optional and therapeutically related terms
- define terms
- describe pharmaceutical composition
- introduce compounds of formula
- describe embodiments of compounds
- describe pharmaceutical composition embodiments
- describe method of treating cancer
- describe method of reducing tumor size
- describe method of constructing protein target structure
- introduce chemical dataset
- describe PSSM and sequence logo representation
- retrieve GAB1 PH domain sequence
- predict secondary structure
- perform homology modeling
- refine homology models
- perform MD simulations
- perform virtual screening
- perform protein pharmacophore modeling
- refine PH domain-inhibitor complex structures
- calculate PMF-based binding free energy
- calculate other terms for binding free energy
- perform SPR spectroscopy binding assays
- perform cellular proliferation assay
- inhibit GAB1 and IRS1 phosphorylation
- evaluate selectivity of inhibitors
- calculate experimental binding free energies
- introduce PH domains
- describe PH domain structure
- motivate fold recognition and sequence alignment
- perform secondary structure-based sequence alignment
- generate PSSMs for β-sheets and α-helix
- predict secondary structure of GAB1 PH domain
- describe GAB1 PH domain structure
- choose templates for homology modeling
- construct homology models of GAB1 PH domain
- perform molecular dynamics simulation
- assess quality of final model
- identify novel inhibitors of GAB1 PH domain
- perform structure-based virtual screening
- define protein pharmacophores
- select docking poses of hits
- validate in silico identified hits
- perform biological evaluation of identified hits
- perform MD simulation of protein-ligand complexes
- calculate absolute binding free energies
- describe ligand-induced conformational changes
- discuss implications for cancer treatment

